Pharmacoeconomics and Safe Medication Use

Patient Case

Questions 6–8 pertain to the following case.

Your institution is considering adding angiotensin II (ATII) to the hospital formulary. Angiotensin II is a non-

catecholamine vasopressor that is FDA approved for increasing blood pressure in distributive shock after publi-

cation of the ATHOS-3 trial. The trial, which compared intravenous ATII with placebo once patients received a

certain dose of vasopressors, showed that patients who received ATII reached a hemodynamic goal more often

than placebo, with no differences in mortality or safety outcomes. Your hospital formulary currently includes the

catecholamine vasopressors and vasopressin. A particular concern of your institution is the cost of ATII therapy

and adherence to formulary restrictions.

When creating the drug evaluation monograph for adding ATII, which recommendation would be most

appropriate to include?

trial.

In considering adding ATII to the formulary, which characteristic of your institution would be most impor-

tant to consider?

shock.

medications.

Angiotensin II was approved by your institution last December, after presentation to the P&T committee.

Which best depicts the month in which the first medication use evaluation should be completed?